Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and ...
Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to severe atopic dermatitis.
Lebrikizumab improved disease severity, skin clearance and symptom relief in children with moderate to severe atopic dermatitis, according to topline results from a phase 3 trial. “Dupilumab [Dupixent ...
Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pediatric patients ...
Everyday Health on MSN
Atopic dermatitis treatment burnout is a real thing
If none of your atopic dermatitis treatments have worked, you may be experiencing burnout (or treatment fatigue). Here's what ...
At the Winter Clinical Dermatology Meeting, April W. Armstrong, MD, MPH, professor and chief of dermatology at the UCLA ...
Our highly trained dermatologists effectively diagnose and treat contact dermatitis in our clinic at University of Utah Health. Contact dermatitis is a skin disorder that occurs when a foreign ...
Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...
A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that ...
Lebrikizumab is an interleukin-13 antagonist approved as Ebglyss for the treatment of adults and pediatric patients with moderate to severe atopic dermatitis.
Occupational contact dermatitis affects North American healthcare workers and is commonly linked to glove rubber accelerators, surfactants, and preservatives, a retrospective study finds.
What is contact dermatitis? Contact dermatitis is a reaction that occurs when something touches your skin and triggers a rash. The rash may appear right away or it could take some time to develop.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results